The Role of Dipeptidyl Peptidase IV (DP IV) Enzymatic Activity in T Cell Activation and Autoimmunity

  title={The Role of Dipeptidyl Peptidase IV (DP IV) Enzymatic Activity in T Cell Activation and Autoimmunity},
  author={Dirk Reinhold and Thilo K{\"a}hne and Andreas Steinbrecher and Sabine Wrenger and Klaus Neubert and Siegfried Ansorge and Stefan Brocke},
  booktitle={Biological chemistry},
Abstract Activated T lymphocytes express high levels of dipeptidyl peptidase IV (DP IV)/CD26. Recent studies support the notion that DP IV may play an important role in the regulation of differentiation and growth of T lymphocytes. This article gives a short overview on DP IV/CD26 expression and effects on immune cells in vitro and in vivo. A major focus of this review are clinical aspects of the function of CD26 on hematopoietic cells and the potential usage of synthetic DP IV inhibitors as… 

Figures and Tables from this paper

Non-substrate peptides influencing dipeptidyl peptidase IV/CD26 activity and immune cell function.

The data suggest that the major envelope proteins p37k of the orthopoxviruses variola virus and vaccinia virus, as well as the B2L antigen of the parapoxvirus orf, that also carry N-terminal Met-Trp-Pro, could mediate immunosuppressive effects.

Dual Inhibition of Dipeptidyl Peptidase IV and Aminopeptidase N Suppresses Inflammatory Immune Responses

The results show that simultaneous application of DP IV and APN inhibitors significantly suppressed DNA synthesis in mitogen‐ or anti‐CD3‐stimulated human T cells in vitro when compared to the use of a single DP IV or APN inhibitor.

Role of dipeptidyl peptidase IV (DP IV)-like enzymes in T lymphocyte activation: investigations in DP IV/CD26-knockout mice

The hypothesis that DP8 and/or DP9 represent additional pharmacological targets for the suppression of T cell proliferation and for anti-inflammatory therapy is supported.

Inhibitors of dipeptidyl peptidase IV and aminopeptidase N target major pathogenetic steps in acne initiation.

First evidence for a functional role of DP IV and APN in the sebaceous gland apparatus and for their inhibitors, used alone or in combination, as completely new substances possibly affecting acne pathogenesis in a therapeutic manner is provided.

PETIR-001, a dual inhibitor of dipeptidyl peptidase IV (DP IV) and aminopeptidase N (APN), ameliorates experimental autoimmune encephalomyelitis in SJL/J mice

It is demonstrated that PETIR-001 exhibits a therapeutic effect on EAE in SJL/J mice, and represents a novel and efficient therapeutic approach for immunotherapy of CNS inflammation.

Dipeptidyl peptidase-4 expression is reduced in Crohn's disease

Possible role of DP IV inhibitors in acne therapy.

The presented data provide evidence that DP IV is expressed on human sebocytes and most likely involved in regulation of sebocyte proliferation and cytokine production. The aminopeptidase inhibitors

Circulating CD26 is negatively associated with inflammation in human and experimental arthritis.




Dipeptidyl peptidase IV in human T lymphocytes. An approach to the role of a membrane peptidase in the immune system.

In the presence of specific inhibitors and antibodies against DP IV several in vitro functions of activated lymphocytes were found to be impaired, including mitogen induced DNA synthesis, immunoglobulin secretion and production of interferon-gamma.

Inhibitors of dipeptidyl peptidase IV/CD26 suppress activation of human MBP-specific CD4+ T cell clones

The dipeptidyl peptidase IV, a membrane enzyme involved in the proliferation of T lymphocytes.

It is concluded that dipeptidyl peptidase IV is involved or might represent a limiting factor in the process of regulation of T lymphocyte proliferation.

Down-regulation of T Cell Activation following Inhibition of Dipeptidyl Peptidase IV/CD26 by the N-terminal Part of the Thromboxane A2 Receptor*

NMR spectroscopy and molecular modeling show that the effect of Trp2-Tat(1–9) could not be explained by significant alterations in the backbone structure and suggest that tryptophan enters favorable interactions with DP IV.

Dipeptidyl peptidase IV in the immune system. Cytofluorometric evidence for induction of the enzyme on activated T lymphocytes.

By means of double fluorescence staining the enzyme has been shown to be restricted nearly exclusively to T lymphocytes even after mitogenic stimulation, and the highest density of DP IV epitopes has been found in cells coexpressing activation markers like receptors for interleukin 2 or transferrin in a high density.

Direct association of adenosine deaminase with a T cell activation antigen, CD26.

CD26, the T cell activation molecule dipeptidyl peptidase IV (DPPIV), associates with a 43-kilodalton protein, which may provide a clue to the pathophysiology of SCID caused by ADA deficiency.

Membrane-bound peptidases of lymphocytes: functional implications.

Results are in favour of the hypothesis that DP IV and AP-N, possibly both in a concerted action, are involved in cytokine/lymphokine mediated signalling between immune cells.

Suppression of arthritis by the inhibitors of dipeptidyl peptidase IV.

The in vivo effects of specific DP IV inhibitors are evaluated using two arthritis models, one which was induced by collagen one by alkyldiamine, and the pharmacological effects of Lys(Z(NO2))-thiazolidide on several immune responses in vitro, in order to determine its mode of action.